covid
Buscar en
Endocrinología y Nutrición
Toda la web
Inicio Endocrinología y Nutrición Concordancia analítica de la tiroglobulina estimulada con tirotropina recombina...
Journal Information
Vol. 54. Issue 4.
Pages 200-204 (April 2007)
Share
Share
Download PDF
More article options
Vol. 54. Issue 4.
Pages 200-204 (April 2007)
Originales
Full text access
Concordancia analítica de la tiroglobulina estimulada con tirotropina recombinante humana y tras privación hormonal previa a la terapia con 131I en pacientes con cáncer diferenciado de tiroides
Concordance between thyroglobulin determinations after diagnostic recombinant human TSH stimulation and after hormone withdrawal prior to 131I therapy in patients with differentiated thyroid cancer
Visits
6868
José M. García Almeidaa,
Corresponding author
josem.jimenezhoyuela.sspa@juntadeandalucia.es

Correspondencia: Dr. J.M. Jiménez-Hoyuela García. Servicio de Medicina Nuclear. Hospital Universitario Virgen de la Victoria. Campus de Teatinos, s/n. 29010 Málaga. España.
, Isabel Aguilar Fernándeza, Alberto Delgado Garcíab, José M. Jiménez-Hoyuela Garcíab, María Dolores Martínez del Valle Torresb, Simeón Ortega Lozanob, Isabel Mancha Doblasa, José L. Pinzón Martína, María José Picón Césara, Damián Zamorano Vázqueza
a Servicio de Endocrinología y Nutrición. Hospital Universitario Virgen de la Victoria. Málaga. España
b Servicio de Medicina Nuclear. Hospital Universitario Virgen de la Victoria. Málaga. España
This item has received
Article information
Objetivos

Comparar los resultados de tiroglobulina obtenidos ante estimulación con tirotropina recombinante humana (rhTSH) con fines diagnósticos y tras privación hormonal previa a la terapia con 131I.

Pacientes y método

Se evaluó a 31 pacientes en seguimiento por cáncer diferenciado de tiroides (CDT) a los que se indicó dosis terapéutica de 131I. Fueron sometidos de forma consecutiva a ambos protocolos de estimulación, y el tratamiento con radioyodo distó 1-2 meses del procedimiento diagnóstico con rhTSH. Se realizaron determinaciones analíticas de TSH, tiroglobulina (Tg) y anticuerpos anti-Tg por métodos inmunométricos.

Resultados

Las medianas de Tg obtenidas tras rhTSH y privación fueron de 1,10 y 1,80ng/ml, respectivamente. Analizados como positivos o negativos, dichos valores mostraron un índice kappa de concordancia de 0,633. Los casos discordantes mostraron una mayor elevación de Tg en estímulo con rhTSH (3 casos) y sólo en 1 caso se obtuvo un resultado negativo con estimulación con rhTSH que luego se positivizó en la dosis ablativa.

Conclusiones

El estímulo con rhTSH consigue elevaciones diagnósticas de TSH en todos los casos aplicados. Los valores de Tg obtenidos con ambos estímulos muestran un grado de concordancia elevado.

Palabras clave:
Tiroglobulina
Tirotropina recombinante humana
Cáncer de tiroides diferenciado
Objectives

To compare the results of thyroglobulin (Tg) determination after diagnostic recombinant human thyroid-stimulating hormone (rhTSH) stimulation and after hormone withdrawal prior to 131I therapy.

Patients and method

Thirty-one patients followed-up for differentiated thyroid cancer were evaluated. In all patients 131I therapy was indicated. All patients underwent both stimulation methods, with an interval of 1-2 months between diagnostic rhTSH administration and radioiodine therapy. Laboratory determinations of TSH, Tg and Tg antibodies were carried out by immunometric methods.

Results

Median Tg values obtained after rhTSH stimulation and hormone withdrawal were 1.10 and 1.80ng/ml, respectively. Considered as positive or negative, these values showed a kappa value of 0.633. Discordant cases showed greater elevation after rhTSH stimulation (3 patients). Only one patient showed a negative result after rhTSH stimulation, which was then positive after the ablative dose.

Conclusions

Stimulus with rhTSH achieved diagnostic elevations of TSH in all patients. Tg levels after both stimulation methods showed a high degree of agreement.

Key words:
Thyroglobulin
Recombinant human TSH
Differentiated thyroid cancer
Full text is only aviable in PDF
Bibliografía
[1.]
J.M. Jiménez-Hoyuela García, J.M. García Almeida, A. Delgado García, I. Aguilar Fernández, M.D. Martínez del Valle Torres, S. Ortega Lozano, et al.
Aplicación de la TSH humana recombinante en el protocolo clínico del cáncer diferenciado de tiroides.
Rev Esp Med Nucl, 24 (2005), pp. 152-160
[2.]
M. Luster, F. Lippi, B. Jarzab, P. Perros, M. Lassmann, C. Reiners, et al.
RhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
Endocr Relat Cancer, 12 (2005), pp. 49-64
[3.]
M. Schlumberger, F. Pacini, W.M. Wiersinga, A. Toft, J.W.A. Smit, F. Sanchez Franco, et al.
Follow-up and management of differentiated thyroid carcinoma: a European perspective in clinical practice.
Eur J Endocrinol, 151 (2004), pp. 539-548
[4.]
R. Robbins, K. Robbins.
Recombinant human thyrotropin and thyroid cancer management.
J Clin Endocrinol Metab, 88 (2003), pp. 1933-1938
[5.]
P.W. Ladenson, M.E. Ewertz, R.A. Dickey.
Practical application of recombinant human thyrotropin testing in clinical practice.
Endocr Pract, 7 (2001), pp. 195-199
[6.]
M. Luster, S.I. Sherman, M.C. Skarulis, J.R. Reynolds, M. Lassmann, H. Hänscheid, et al.
Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma.
Eur J Nucl Med Mol Imaging, 30 (2003), pp. 1371-1377
[7.]
C. Menzel, W.T. Kranert, N. Döbert, M. Diehl, T. Fietz, N. Hamscho, et al.
rhTSH estimulation before radioiodine therapy in thyroid cancer reduces effective half life of 131I.
J Nucl Med, 44 (2003), pp. 1035-1038
[8.]
E.L. Mazzaferri, R.J. Robbins, C.A. Spencer, L.E. Braverman, F. Pacini, L. Wartofsky, et al.
A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma.
J Clin Endocrinol Metab, 88 (2003), pp. 1433-1441
[9.]
W.W. Woodmansee, B.R. Haugen.
Uses of recombinant human TSH in patients with thyroid cancer and nodular goiter.
Clin Endocrinol, 61 (2004), pp. 163-173
[10.]
R.J. Robbins, J.T. Chon, M. Fleisher, S.M. Larson, R.M. Tuttle.
Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma?.
J Clin Endocrinol Metab, 87 (2002), pp. 3242-3247
[11.]
J.R. Landis, G.G. Koch.
The measurement of observer agreement for categorical data.
Biometrics, 33 (1977), pp. 159-174
[12.]
C.A. Meier, L.E. Braverman, S.A. Ebner, I. Veronikis, G.H. Daniels, D.S. Ross, et al.
Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (Phase I/II study).
J Clin Endocrinol Metab, 78 (1994), pp. 188-196
[13.]
P.W. Ladenson, L.E. Braverman, E.L. Mazzaferri, F. Brucker-Davis, D.S. Cooper, J.R. Garber, et al.
Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma.
N Engl J Med, 337 (1997), pp. 888-896
[14.]
B.R. Haugen, F. Pacini, C. Reiners, M. Schlumberger, P.W. Ladenson, S.I. Sherman, et al.
A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer.
J Clin Endocrinol Metab, 84 (1999), pp. 3877-3885
[15.]
R.J. Robbins, R.M. Tuttle, R.N. Sharaf, S.M. Larson, H.K. Robbins, R.A. Ghossein, et al.
Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma.
J Clin Endocrinol Metab, 86 (2001), pp. 619-625
[16.]
F. Pacini, E. Molinaro, F. Lippi, M.G. Castagna, L. Agate, C. Ceccarelli, et al.
Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma.
J Clin Endocrinol Metab, 86 (2001), pp. 5686-5690
[17.]
C. Eustatia-Rutten, J.N. Smit, J.A. Romijn, E.P. Van der Kleij-Corssmit, A.H. Pereira, M.P. Stokkel, et al.
Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis.
Clin Endocrinol, 61 (2004), pp. 61-74
Copyright © 2007. Sociedad Española de Endocrinología y Nutrición
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos